-
Stephan Moll, MD writes (last updated: Sept 9th, 2020)… Background: Hospitalized patients with COVID-19 are at increased risk for thrombosis – DVT, PE, and may be pulmonary micro-vascular thrombosis that possibly contributes to respiratory failure; arterial events appear to occur less commonly. Scientific/clinical data on prevalence of thrombosis, best prevention, and optimal therapy are limited.…
-
Lixiana® (Edoxaban), the 4th of the big new oral blood thinners in development (the other big 3 being Dabigatran = Pradaxa, Rivaroxaban = Xarelto, and Apixaban = Eliquis), is now commercially available in Japan (July 19th, 2011 press release here). It is available as once daily dosing for prevention of blood clots in the legs…
-
Edoxaban (Savaysa®), the 4th of the big new oral anticoagulants in development (the other big 3 being Dabigatran = Pradaxa, Rivaroxaban = Xarelto, and Apixaban = Eliquis), is now commercially available in Japan (July 19th, 2011 press release here), available as once daily dosing for VTE prevention after orthopedic surgeries (hip and knee replacement and…
-
Once or twice daily injections of s.c. anticoagulants for prolonged periods of time can be bothersome and unacceptable for the patient. Use of a once weekly exchanged s.c. port, called Insuflon, can make longer-term s.c. anticoagulant therapy easier and more tolerable.
-
Having to take shots of a blood thinner injected under the skin (subcutaneously = s.c.) once or twice daily for prolonged periods of time can be bothersome and uncomfortable. Use of a once weekly exchanged s.c. port, called Insuflon, can make it easier for a number of patients.
-
The CDC today published recommendations on use of contraceptive methods for non-breast feeding women in the post-partum period (full text is here). The key recommendations are as follows:
-
The CDC today published recommendations on use of birth control methods for non-breast feeding women after child birth (full text is here). The key recommendations are as follows:
-
Today the FDA approved the oral anticoagulant Xarelto (rivaroxaban) for DVT prevention in patients undergoing knee or hip replacement surgery. This is good news
-
On July 1st, the FDA approved the oral blood thinner Xarelto (rivaroxaban) for the prevention of deep vein thrombosis (DVT) in patients undergoing knee or hip replacement surgery.
-
Pulmonary hypertension affects up to 4 % of PE patient and typically occurs within the first 2 years after a PE. It is defined as a mean pulmonary artery pressure of ≥ 25 mm Hg by right heart catheterization, with normal pulmonary capillary wedge pressure, and elevated pulmonary vascular resistance. Pulmonary hypertension occurring after an…
-
Blood clots in the lung (pulmonary embolism, PE) often completely dissolve within a few weeks or months and a patient’s symptoms of shortness and breath and chest pain disappear. Many people return to their normal self and have no physical limitations thereafter. Other people have some residual symptoms of shortness of breath or chest discomfort,…
A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center
Clot Connect 